COMMUNIQUÉS West-GlobeNewswire

Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
21/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for [...]
Emerald Health Therapeutics to Hold Conference Call on First Quarter 2019 Financial Results on May 31st
21/05/2019
VANCOUVER, British Columbia, May 21, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc.(“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31 [...]
BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
21/05/2019
NDA filing on-track for Q4 2019 RESEARCH TRIANGLE PARK, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the randomized (n=121), double-blind, placebo-controlled [...]
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
21/05/2019
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
21/05/2019
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics ® , today announces expansion of space and testing [...]
Transactions in relation to share buyback program
21/05/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]
Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
21/05/2019
Pratteln, Switzerland, May 21, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces its collaboration with the Biozentrum of the University of Basel to advance gene therapy research for the treatment of LAMA2-deficient [...]
Motif Bio to Present Iclaprim Data at ASM Microbe 2019
21/05/2019
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have [...]
Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis
21/05/2019
Publication of GKT831 data in the Journal of Hepatology Data consistent with anti-fibrotic activity recently demonstrated in PBC Phase 2 trial of GKT831 Data further support broad therapeutic potential of GKT831 in [...]
Une étude préclinique du GKT831 montre une régression rapide de la fibrose cholestatique dans un modèle de fibrose hépatique avancée
21/05/2019
Publication des donnees du GKT831 dans le Journal of Hepathology Les données répliquent l’activité anti-fibrotique récemment démontrée dans l’étude de phase 2 avec le GKT831 dans la cholangite biliaire primitive Les [...]
Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE
21/05/2019
Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach This appointment underlines the importance of the bioactive compounds and the [...]
Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
21/05/2019
- Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing - Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the Netherlands, and [...]
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
21/05/2019
Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of Directors Aegerion will continue to make available to patients its two [...]
AIT Therapeutics Presents Data at the 2019 American Thoracic Society Conference in Dallas, TX
21/05/2019
Oral presentation part of a mini-symposium on NTM held on Monday, May 20, 2019 GARDEN CITY, N.Y. and REHOVOT, Israel, May 20, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical [...]
Pacific Health Care Organization, Inc. First Quarter 2019 Results
21/05/2019
Newport Beach, CA, May 20, 2019 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its quarterly report [...]
Akers Biosciences Reports Q1 2019 Earnings
20/05/2019
Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the “Company”), a developer of rapid [...]
CorVel Announces Fiscal Year Earnings Release Webcast
20/05/2019
IRVINE, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- Event: Fiscal Year Earnings Release Webcast Hosts: Michael Combs, President and Chief Executive Officer Brandon O’Brien, Chief Financial Officer Date: Thursday, May 30, [...]
Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update
20/05/2019
RUTHERFORD, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data [...]
Voyager Therapeutics Announces Management Updates
20/05/2019
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]

Pages